CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results

Go back to CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results

Johnson & Johnson (JNJ) PT Lowered to $175 at RBC Capital

April 17, 2024 7:05 AM EDT

RBC Capital analyst Shagun Singh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $175.00 (from $181.00) while maintaining a Outperform rating.

The analyst comments "JNJ's stock traded modestly lower post-Q1'24, where it delivered inline sales and EPS beat. JNJ tightened FY24 operational guidance... More

Johnson & Johnson (JNJ) PT Lowered to $170 at BofA Securities

April 17, 2024 5:12 AM EDT

BofA Securities analyst Geoff Meacham lowered the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $180.00) while maintaining a Neutral rating.

The analyst comments "JNJ shares traded down today (-2.0%; DRG -0.3%) despite a solid 1Q and reported guidance midpoint unchanged, which we suspect was due to disappointing Carvykti sales (-1% q/q) and Vision business (-3% y/y).... More